无法切除的肝内胆管癌:TARE还是TACE,选择哪一个?
Maria Adriana Cocozza1, Lorenzo Braccischi1, Antonio De Cinque2
1Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Frontiers in gastroenterology (Lausanne, Switzerland)
|March 13, 2026
概括
肝脏内胆管癌 (ICC) 的管理包括全身化疗和干预性动脉内疗法 (IAT),如TACE和TARE. 目前的证据表明,TACE和TARE为不可操作的ICC提供了类似的生存益处,但对比数据有限.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 干预性放射学 干预性放射学
- 在瘤学瘤学.
背景情况:
- 肝脏内胆管癌 (ICC) 是一种正在上升的肝癌,通常在晚期被诊断出来.
- 手术切除是治愈性的,但对于大多数患者来说是不可行的.
- 目前的一线化疗提供了有限的生存益处.
研究的目的:
- 审查目前关于干预性动脉内疗法 (IAT) 管理ICC的证据.
- 为了比较跨动脉化学栓塞 (TACE) 和跨动脉放射栓塞 (TARE) 的疗效.
主要方法:
- 对国际刑事法院IAT的当前文献的审查.
- 对比TACE和TARE的研究分析.
- 评估治疗对控制局部疾病和改善生存的疗效.
主要成果:
- 广泛使用的TACE和TARE在控制ICC和改善生存率方面表现出有效性.
- 目前的文献缺乏关于TACE与TARE优势的确证据.
- 分析表明TACE和TARE的结果类似,但有局限性.
结论:
- 包括TACE和TARE在内的IAT在管理无法操作的ICC方面发挥着重要作用.
- 需要进一步进行比较研究,才能确定TACE或TARE的优势.
- 证据是基于单一中心研究,具有固有的偏见和异质性.
更多相关视频
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.9K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.4K
相关概念视频
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K